Under the agreement, both sides will advance project development via milestone-based cooperation and establish a coordinated financing mechanism simultaneously. Qilu Pharmaceutical will make milestone investments in MoMed Biotech in this round and future stages. This marks the maiden collaboration between the two parties in innovative drug R&D, and will also forge a new path for the development of selective molecules targeting specific targets.

Qilu Pharmaceutical stated that as a leading domestic pharmaceutical enterprise, it consistently prioritizes the exploration and application of cutting-edge technologies represented by AI to elevate innovative R&D capacity and efficiency, and makes proactive industrial layouts. It looks forward to integrating its long-standing R&D experience and strengths with MoMed Biotech’s AI pharmaceutical platform rooted in target protein mechanism research, so as to address unmet clinical needs and bring benefits to patients worldwide.

MoMed Biotech remarked that the cooperation stands as a major breakthrough in its collaborative innovative drug development, proving growing recognition of its platform value by major pharmaceutical firms. Going forward, the company will stay focused on original technological innovation, deepen the application of AI and advanced computational biology in drug discovery, accelerate the identification and translation of innovative candidate molecules, and deliver more clinically and commercially viable therapies to patients.

Taking this partnership as a new starting point, MoMed Biotech will keep optimizing platform-based R&D and project delivery capabilities, build an open and collaborative innovation ecosystem, and cooperate with more industrial partners to advance the AI pharmaceutical sector and domestic original drug research to new heights.